Introduction: Success of modern cancer therapy leads to a decline in death rates for cancer patients. Cardiovascular disease (CVD) is now a leading cause of long-term morbidity and mortality among cancer survivors. There is increasing need to be more vigilant in the use of cardioprotective therapies for primary and secondary prevention of cardiovascular diseases in patients living with cancer. This study aims to examine the use of cardioprotective therapies in patients with or without previous history of cancer admitted to cardiology.
Methods and Results: Patients (n = 333, mean age: 65 ± 13 yrs) who were admitted to cardiology unit at John Hunter Hospital for either acute or chronic CVD from July to November 2018. N = 76 (23%) of patients had a history of cancer (Hx Ca) as documented in case notes at the time of admission. There was no difference in the prevalence of cardiac ischaemia, hypertension, dyslipidaemia, diabetes, or heart failure, but significantly higher atrial fibrillation in patients with Hx Ca (26%) vs. those without (16%). There was underuse of cardiovascular medications in patients with Hx Ca vs those without: antiplatelets (53% vs. 73%, p < 0.01); ␤-blockers (61% vs 70%, p = 0.17), ACEi/ARB (50% vs 61%, p = 0.1), and statins (59% vs 78%, p < 0.01). On multivariate analysis, patients with Hx of Ca had significantly lower usage of statins adjusted for age, BMI, gender, and cardiovascular risk factors.
Conclusions: Cardioprotective therapies appear to be under-utilised in patients with previous history of cancer with comparable CV risk factors. Strategies are required to increase cardioprotective pharmacotherapies in these patients. Aims: Retrospective studies have suggested improved survival outcomes with the use of Extracorporeal membrane oxygenation (ECMO) in refractory cardiac arrest (ECPR). We sought to prospectively assess outcomes in refractory cardiac arrest treated with ECPR.
Methods: The 2CHEER trial (mechanical CPR, Hypothermia, ECMO and Early Reperfusion) is a multi-centre, prospective cohort study conducted at Royal Prince Alfred and St Vincent's Hospitals, Sydney, NSW with the NSW Ambulance service. Patients aged 12-70 years with refractory cardiac arrest were enrolled into the 2CHEER treatment bundle.
Results: From 2016 to 2018, 25 patients were eligible for the 2CHEER protocol (13 (52%) OHCA, 12 (48%) IHCA; 17 (68%) males. Median age was 57 (IQR 39-65) years and all patients received bystander CPR. VT/VF was initial rhythm in 17 (68%) of patients. ECMO flow was established in all patients; median time from collapse until initiation of ECMO 57 (IQR 38-73) min. Percutaneous coronary intervention was performed in 18 (72%) patients. Median duration of ECMO support was 52 (IQR 24 -108) hours. Survival to hospital discharge was 64% (7) for IHCA and (36% (4) for OHCA. Survival with favourable neurological outcome (CPC 1 or 2) occurred in all survivors; (11/25) (44%) of total patients. Time to ECMO flow was significantly associated with survival p < 0.001. Initial rhythm and percutaneous intervention were not.
Conclusion: Treatment of refractory cardiac arrest with ECMO is feasible and associated with very good neurologically intact survival. 
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Introduction: Living situation is an important part of the assessment of functional status and is often used as a surrogate marker of frailty. Little is known about the impact of living situation on management and outcomes of elderly patients presenting with NSTEMI.
Methods: A retrospective analysis of 956 consecutive patients aged >85 years presenting with NSTEMI between 2010-2018 were included. Home status was defined as independent, low-level care (LLC) or high-level care (HLC). Guideline-directed medical therapy (GDMT) included aspirin, beta-blockers and statins. The primary outcome was all-cause mortality.
Results: Of the 956 patients included, 575 (60.1%) lived independently, 252 (26.4%) in LLC and 129 (13.5%) in HLC. Those in LLC and HLC were significantly less likely to be prescribed GDMT (p < 0.001). These patients were also less likely to undergo invasive coronary angiography (15% in independent living, vs 2% in LLC, 0 in HLC, p < 0.001). Over a mean follow-up of 1.3 years, 444 patients died (46.4). Independent living was associated with improved survival (HR 0.66 95%CI 0.55-0.81, p < 0.001). LLC living was not an independent predictor of mortality (HR 1.2
